肝线粒体在非酒精性脂肪性肝病临床进程中的代谢功能变化

摘要/Abstract

摘要： 非酒精性脂肪性肝病(NAFLD)已成为全球最常见的慢性肝病病因,但目前发病机制尚未完全明确,临床治疗措施有限。近年来,肝线粒体相关变化作为NAFLD病理生理机制中的重要角色受到关注,营养代谢负荷持续增加引起的肝线粒体代谢功能障碍、生物发生异常等成为NAFLD疾病进展的重要表现。本文主要对NAFLD临床病程中肝线粒体代谢功能变化的研究进展进行综述。

关键词: 非酒精性脂肪性肝病, 线粒体代谢功能, 线粒体生物发生, 临床研究

张明明, 汪艳. 肝线粒体在非酒精性脂肪性肝病临床进程中的代谢功能变化[J]. 肝脏, 2023, 28(4): 393-395.

[1] Powell EE, Wong VWS, Rinella M. Non-alcoholic fatty liver disease. Lancet, 2021,397(10290):2212-2224.
[2] Younossi ZM, Golabi P, Paik JM, et al. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology,2023,77(4):1335-1347.?
[3] Pafili K, Roden M. Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans. Mol Metab,2021,50:101122.
[4] Begriche K, Massart J, Robin MA, et al. Mitochondrial adaptations and dysfunctions in nonalcoholic fatty liver disease. Hepatology,2013,58(4):1497-1507.
[5] Koliaki C, Szendroedi J, Kaul K, et al. Adaptation of Hepatic Mitochondrial Function in Humans with Non-Alcoholic Fatty Liver Is Lost in Steatohepatitis. Cell Metabolism,2015,21(5):739-746.
[6] Moore MP, Cunningham RP, Meers GM, et al. Compromised hepatic mitochondrial fatty acid oxidation and reduced markers of mitochondrial turnover in human NAFLD. Hepatology,2022,76(5):1452-1465.
[7] Pedersen JS, Rygg MO, Chr? is K, et al. Influence of NAFLD and bariatric surgery on hepatic and adipose tissue mitochondrial biogenesis and respiration. Nat Commun, 2022,13(1):2931.
[8] Petersen KF, Befroy DE, Dufour S, et al. Assessment of Hepatic Mitochondrial Oxidation and Pyruvate Cycling in NAFLD by (13)C Magnetic Resonance Spectroscopy. Cell Metab,2016,24(1):167-171.
[9] Luukkonen PK, Dufour S, Lyu K, et al. Effect of a ketogenic diet on hepatic steatosis and hepatic mitochondrial metabolism in nonalcoholic fatty liver disease. Proc Natl Acad Sci U S A,2020,117(13):7347-7354.
[10] Fromenty B, Roden M. Mitochondrial alterations in fatty liver diseases. J Hepatol,2023,78(2):415-429.
[11] Gray MW, Burger G, Lang BF. The origin and early evolution of mitochondria. Genome Biol,2001,2(6):REVIEWS1018.
[12] Kroon AM, Van den Bogert C. Biogenesis of mitochondria and genetics of mitochondrial defects. J Inherit Metab Dis,1987,10 Suppl 1:54-61.
[13] Sickmann A, Reinders J, Wagner Y, et al. The proteome of Saccharomyces cerevisiae mitochondria. Proc Natl Acad Sci U S A,2003,100(23):13207-13212.
[14] Foster LJ, de Hoog CL, Zhang Y, et al. A mammalian organelle map by protein correlation profiling. Cell,2006,125(1):187-199.
[15] Heldt HW. Energy metabolism in mitochondria. Angew Chem Int Ed Engl, 1972,11(9):792-798.
[16] Spinelli JB, Haigis MC. The multifaceted contributions of mitochondria to cellular metabolism. Nat Cell Biol,2018,20(7):745-754.
[17] Green DR, Reed JC. Mitochondria and apoptosis. Science,1998,281(5381):1309-1312.
[18] Schirrmacher V. Mitochondria at Work: New Insights into Regulation and Dysregulation of Cellular Energy Supply and Metabolism. Biomedicines,2020,8(11):526.
[19] Chance B, Williams GR. Respiratory enzymes in oxidative phosphorylation. I. Kinetics of oxygen utilization. J Biol Chem,1955,217(1):383-393.
[20] Marí M, Morales A, Colell A, et al. Mitochondrial glutathione, a key survival antioxidant. Antioxid Redox Signal, 2009,11(11):2685-2700.
[21] Musso G, Gambino R, Cassader M. Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD). Prog Lipid Res,2009,48(1):1-26.
[22] Pollitt RJ. Disorders of mitochondrial long-chain fatty acid oxidation. J Inherit Metab Dis, 1995,18(4):473-490.
[23] He Q, Chen Y, Wang Z, et al. Cellular Uptake, Metabolism and Sensing of Long-Chain Fatty Acids. Front Biosci (Landmark Ed),2023,28(1):10.
[24] Eaton S. Control of mitochondrial beta-oxidation flux. Prog Lipid Res, 2002,41(3):197-239.
[25] Azzu V, Vacca M, Virtue S, et al. Adipose Tissue-Liver Cross Talk in the Control of Whole-Body Metabolism: Implications in Nonalcoholic Fatty Liver Disease. Gastroenterology,2020,158(7):1899-1912.
[26] Rui L. Energy metabolism in the liver. Compr Physiol,2014,4(1):177-197.
[27] Ploumi C, Daskalaki I, Tavernarakis N. Mitochondrial biogenesis and clearance: a balancing act. FEBS J,2017,284(2):183-195.
[28] Andreux PA, Houtkooper RH, Auwerx J. Pharmacological approaches to restore mitochondrial function. Nat Rev Drug Discov,2013,12(6):465-483.
[29] Shpilka T, Haynes CM. The mitochondrial UPR: mechanisms, physiological functions and implications in ageing. Nat Rev Mol Cell Biol,2018,19(2):109-120.
[30] Hernández EÁ, Kahl S, Seelig A, et al. Acute dietary fat intake initiates alterations in energy metabolism and insulin resistance. J Clin Invest,2017,127(2):695-708.
[31] Blüher M. Metabolically Healthy Obesity. Endocr Rev,2020,41(3):bnaa004.
[32] Sunny NE, Parks EJ, Browning JD, et al. Excessive hepatic mitochondrial TCA cycle and gluconeogenesis in humans with nonalcoholic fatty liver disease. Cell Metab, 2011,14(6):804-810.
[33] Cortez-Pinto H, Chatham J, Chacko VP, et al. Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis: a pilot study. JAMA,1999,282(17):1659-1664.
[34] Pérez-Carreras M, Del Hoyo P, Martín MA, et al. Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis. Hepatology, 2003,38(4):999-1007.
[35] Serviddio G, Bellanti F, Tamborra R, et al. Uncoupling protein-2 (UCP2) induces mitochondrial proton leak and increases susceptibility of non-alcoholic steatohepatitis (NASH) liver to ischaemia-reperfusion injury. Gut,2008,57(7):957-965.
[36] Moore MP, Cunningham RP, Meers GM, et al. Compromised hepatic mitochondrial fatty acid oxidation and reduced markers of mitochondrial turnover in human NAFLD. Hepatology,2022,76(5):1452-1465.
[37] Ooi GJ, Meikle PJ, Huynh K, et al. Hepatic lipidomic remodeling in severe obesity manifests with steatosis and does not evolve with non-alcoholic steatohepatitis. J Hepatol, 2021,75(3):524-535.

肝线粒体在非酒精性脂肪性肝病临床进程中的代谢功能变化

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	李旭辉, 范建高. 非酒精性脂肪性肝病更名代谢相关脂肪性肝病的争议[J]. 肝脏, 2023, 28(5): 505-506.
[2]	钟献凤, 陈桂娥, 陈彦婵, 黄健源. 超声E成像及MR mDixon序列检查对非酒精性脂肪性肝病的诊断价值[J]. 肝脏, 2023, 28(5): 585-589.
[3]	贾刚刚, 卢利霞, 李斌, 林通, 王曈辉, 王秀锋, 马俊, 何毅刚, 于晓辉. 微生物群靶向治疗在非酒精性脂肪性肝病中的临床研究进展[J]. 肝脏, 2023, 28(5): 621-624.
[4]	王资隆, 饶慧瑛. PPARα激动剂治疗非酒精性脂肪性肝病的研究进展[J]. 肝脏, 2023, 28(4): 396-397.
[5]	刘璐, 朱锦舟, 刘晓琳, 王超, 殷民月, 高静雯, 许春芳. 基于机器学习构建非酒精性脂肪性肝病预测模型[J]. 肝脏, 2023, 28(4): 469-473.
[6]	李少君, 李静, 于佳新. 血清PCSK9水平对老年非酒精性脂肪性肝病动脉粥样硬化程度及预后的判断价值[J]. 肝脏, 2023, 28(4): 479-482.
[7]	苏佩华, 魏梦平, 赵彩彦. 慢性乙型肝炎合并非酒精性脂肪性肝病对肝细胞癌发生及全因死亡影响的meta分析[J]. 肝脏, 2023, 28(3): 299-304.
[8]	刘晓慧, 勾钰淞, 梁珊, 任弘, 李强, 段威, 张晶. 最大摄氧量与男性非酒精性脂肪性肝病患者肝脏脂肪含量相关[J]. 肝脏, 2023, 28(3): 355-359.
[9]	王伟, 葛亮, 余宁, 熊晓芸. 非肥胖型非酒精性脂肪性肝病组织学特征及临床结局评价[J]. 肝脏, 2023, 28(3): 360-363.
[10]	陆新元, 丛文铭. 非酒精性脂肪性肝病中肝细胞死亡模式的研究进展[J]. 肝脏, 2023, 28(2): 145-148.
[11]	范芯铷, 晏梓钧, 王庆, 汪慧. 青年消瘦型非酒精性脂肪性肝病相关肝细胞癌2例[J]. 肝脏, 2023, 28(2): 151-154.
[12]	厉绾, 韩艳霞, 谢寿珍, 马颖才, 杨永耿, 李萍英. 减重对CHB和(或)NAFLD患者肝纤维化及脂肪肝程度的影响[J]. 肝脏, 2023, 28(2): 203-206.
[13]	赵建红, 李鸿彬, 程相超, 郭彦伟. 非酒精性脂肪性肝病患者颈动脉内膜中层厚度、颈股动脉脉搏波传导速度分析[J]. 肝脏, 2023, 28(2): 214-217.
[14]	杨诚, 杨华升, 胡建华, 张丽丽, 徐琛. 终末期肝病与营养相关研究的可视化分析[J]. 肝脏, 2023, 28(1): 65-69.
[15]	杨永勤, 冯巩, 李嵘, 孙雪梅, 陈敏, 贺娜. 非酒精性脂肪性肝病与瞬时弹性成像技术研究热点与前沿:基于Web of Sciense数据的实证研究[J]. 肝脏, 2022, 27(9): 1015-1020.